Simple Drug May Save Thousands of Bleeding Mothers

Roughly every six minutes, a woman somewhere in the world bleeds to death in child birth. But a new medical trial shows that there is a way of combating this global problem which is prevalent in Nigeria and Ethiopia.

Video

  • 10 November 2017
    Can Women Dying After Childbirth Be Prevented?
    Publisher:
    The WOMAN Trial
    Publication Date:

    Every year 14 million mothers develop severe bleeding after childbirth or postpartum haemorrhage (PPH) as it is also known, and about 2% of them will die, with an average of 2-4 hours from the start of bleeding to death. The WOMAN trial aims to provide the research based information, as to whether an old drug, tranexamic acid (TXA), can improve the outcomes for women who develop this life-threatening condition, and ultimately save lives. TXA is a drug developed in the 1950's, which is commonly

    see more »

Survivor of postpartum haemorrhage in Nigeria holds her child. The WOMAN trial has found that a simple drug called tranexamic acid, a blood clot stabiliser first discovered in Japan in the 1950s, could cut deaths from bleeding by a third if given to women within three hours.

  • Africa:   The Trial Explained

    The WOMAN Trial, 10 November 2017

    The WOMAN trial, coordinated by the London School of Hygiene & Tropical Medicine (LSHTM) Clinical Trials Unit (CTU) is an international clinical trial of the effect of… Read more »

AllAfrica publishes around 600 reports a day from more than 90 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.